Marinus Pharmaceuticals, Inc. (MRNS) News
Filter MRNS News Items
MRNS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MRNS News Highlights
- MRNS's 30 day story count now stands at 11.
- Over the past 20 days, the trend for MRNS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- BIO, ACET and LH are the most mentioned tickers in articles about MRNS.
Latest MRNS News From Around the Web
Below are the latest news stories about Marinus Pharmaceuticals Inc that investors may wish to consider to help them evaluate MRNS as an investment opportunity.
Marinus slips to a 52-week low as analysts react to delays for clinical studiesMarinus (MRNS -20.5%) has recorded the biggest intraday loss since March 2020 on Wednesday to approach a 52-week low after the clinical-stage pharma company announced delays for several clinical programs involving an IV formulation of its only product candidate, ganaxolone. The company attributed the setback to COVID-19 impact on enrollment and... |
Marinus Pharma Delays Status Epilepticus, IV Ganaxolone Clinical Trials Into 2023Marinus Pharmaceuticals Inc (NASDAQ: MRNS) expects data from the RAISE Phase 3 trial of ganaxolone in refractory status epilepticus in 2H of 2023. Earlier data from the trial was expected in 2H of 2022. The delay is due to the impact of the COVID-19 omicron variant and an interruption of clinical supply material associated with IV ganaxolone. Marinus has temporarily paused the RAISE trial after routine monitoring of stability batches of clinical supply material indicated that it became necessary |
Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical TrialsRADNOR, Pa., February 22, 2022--Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials |
Marinus Pharmaceuticals to Provide Business Update and Announce Preliminary Fourth Quarter 2021 Financial Results on March 21, 2022RADNOR, Pa., February 16, 2022--Marinus Pharmaceuticals to Provide Business Update and Announce Preliminary Fourth Quarter 2021 Financial Results on March 21, 2022 |
Is Marinus Pharmaceuticals (NASDAQ:MRNS) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the... |
Analysts Are Bullish on These Healthcare Stocks: Laboratory (LH), Marinus (MRNS)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Laboratory (LH – Research Report), Marinus (MRNS – Research Report) and Denali Therapeutics (DNLI – Research Report) with bullish sentiments. Laboratory (LH) Jefferies analyst Brian Tanquilut maintained a Buy rating on Laboratory yesterday and set a price target of $330.00. The company's shares closed last Thursday at $282.19. According to TipRanks. |
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)RADNOR, Pa., February 10, 2022--Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) |
Marinus (MRNS) Gets a Buy Rating from Ladenburg Thalmann & Co.Ladenburg Thalmann & Co. analyst Michael Higgins reiterated a Buy rating on Marinus (MRNS – Research Report) today and set a price target of $20.00. The company's shares closed last Thursday at $10.14, close to its 52-week low of $9.10. According to TipRanks.com, Higgins is a 3-star analyst with an average return of 4.0% and a 30.4% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Zynerba Pharmaceuticals, and Armata Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Marinus with a $28.50 average price target, which is a 182.5% upside from current levels. |
Analysts Are Bullish on These Healthcare Stocks: Adicet Bio (ACET), Marinus (MRNS)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Adicet Bio (ACET – Research Report) and Marinus (MRNS – Research Report) with bullish sentiments. Adicet Bio (ACET) H.C. Wainwright analyst Edward White reiterated a Buy rating on Adicet Bio today and set a price target of $35.00. The company's shares closed last Thursday at $12.13. According to TipRanks. |
Marinus (MRNS) Gets a Buy Rating from JMP SecuritiesIn a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Marinus (MRNS – Research Report), with a price target of $22.00. The company's shares closed last Thursday at $10.05, close to its 52-week low of $9.10. According to TipRanks.com, Butler 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -2.7% and a 37.9% success rate. Butler covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, ACADIA Pharmaceuticals, and Aquestive Therapeutics. Currently, the analyst consensus on Marinus is a Strong Buy with an average price target of $26.60. |